Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000726285 | SCV000343445 | uncertain significance | not provided | 2018-05-15 | criteria provided, single submitter | clinical testing | |
Athena Diagnostics Inc | RCV000279795 | SCV000614745 | uncertain significance | not specified | 2017-06-26 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001850443 | SCV002132094 | uncertain significance | Autosomal recessive limb-girdle muscular dystrophy type 2K; Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B1; Walker-Warburg congenital muscular dystrophy | 2022-08-21 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 506 of the POMT1 protein (p.Thr506Met). This variant is present in population databases (rs201220016, gnomAD 0.02%). This variant has not been reported in the literature in individuals affected with POMT1-related conditions. ClinVar contains an entry for this variant (Variation ID: 289144). Algorithms developed to predict the effect of missense changes on protein structure and function output the following: SIFT: "Tolerated"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0". The methionine amino acid residue is found in multiple mammalian species, which suggests that this missense change does not adversely affect protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000726285 | SCV003811823 | uncertain significance | not provided | 2022-08-02 | criteria provided, single submitter | clinical testing |